Menu
Back to User profile » Professor Girolamo Pelaia
Papers published by Professor Girolamo Pelaia:
Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study
Le TT, Emmanuel B, Katial R, Tran TN, Kwiatek JJ, Cohen DS, Daniel SR, Cao Y, Shih VH, Melcón MG, Devouassoux G, Pelaia G
Journal of Asthma and Allergy 2024, 17:313-324
Published Date: 5 April 2024
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
Cameli P, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Canonica GW, Caruso C, Centanni S, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Senna G, Vultaggio A, Benci M, Boarino S, Menzella F
Journal of Asthma and Allergy 2024, 17:273-290
Published Date: 27 March 2024
Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?
Pelaia C, Giacalone A, Ippolito G, Pastore D, Maglio A, Piazzetta GL, Lobello N, Lombardo N, Vatrella A, Pelaia G
Pragmatic and Observational Research 2024, 15:45-51
Published Date: 11 March 2024
Exacerbation Burden in COPD and Occurrence of Mortality in a Cohort of Italian Patients: Results of the Gulp Study
Santus P, Di Marco F, Braido F, Contoli M, Corsico AG, Micheletto C, Pelaia G, Radovanovic D, Rogliani P, Saderi L, Scichilone N, Tanzi S, Vella M, Boarino S, Sotgiu G, Solidoro P
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:607-618
Published Date: 1 March 2024
Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
Pelaia C, Ferrante Bannera A, Rotundo FL, Tropea FG, Armentaro G, Maglio A, Sciacqua A, Vatrella A, Pelaia G
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:995-1002
Published Date: 26 May 2023
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study
Senna G, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Cameli P, Canonica GW, Caruso C, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, Rizzoli S, Zullo A, Boarino S, Palmisano M, Rossi A, Vitiello G, Centanni S
Journal of Asthma and Allergy 2022, 15:1593-1604
Published Date: 10 November 2022
Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
Pelaia C, Lombardo N, Busceti MT, Piazzetta G, Crimi C, Calabrese C, Vatrella A, Pelaia G
Journal of Asthma and Allergy 2021, 14:1165-1172
Published Date: 24 September 2021
Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies
Pelaia C, Vatrella A, Gallelli L, Lombardo N, Sciacqua A, Savino R, Pelaia G
Drug Design, Development and Therapy 2021, 15:1275-1284
Published Date: 23 March 2021
Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
Pelaia C, Crimi C, Benfante A, Caiaffa MF, Calabrese C, Carpagnano GE, Ciotta Jnr D, D'Amato M, Macchia L, Nolasco S, Pelaia G, Pellegrino S, Scichilone N, Scioscia G, Spadaro G, Valenti G, Vatrella A, Crimi N
Journal of Asthma and Allergy 2021, 14:163-173
Published Date: 22 February 2021
Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
Menzella F, Bonavia M, Bonini M, D'Amato M, Lombardo S, Murgia N, Patella V, Triggiani M, Pelaia G
Journal of Asthma and Allergy 2021, 14:149-161
Published Date: 22 February 2021
Early management of COPD: where are we now and where do we go from here? A Delphi consensus project
Di Marco F, Balbo P, de Blasio F, Cardaci V, Crimi N, Girbino G, Pelaia G, Pirina P, Roversi P, Santus P, Scichilone N, Vatrella A, Pasqualetti P, Carone M
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:353-360
Published Date: 4 February 2019
LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:3115-3130
Published Date: 4 October 2018
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G
Drug Design, Development and Therapy 2018, 12:619-628
Published Date: 21 March 2018
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G
Drug Design, Development and Therapy 2017, 11:3137-3144
Published Date: 30 October 2017
Targeted therapy in severe asthma today: focus on immunoglobulin E
Pelaia G, Canonica GW, Matucci A, Paolini R, Triggiani M, Paggiaro P
Drug Design, Development and Therapy 2017, 11:1979-1987
Published Date: 29 June 2017
Theophylline action on primary human bronchial epithelial cells under proinflammatory stimuli and steroidal drugs: a therapeutic rationale approach
Gallelli L, Falcone D, Cannataro R, Perri M, Serra R, Pelaia G, Maselli R, Savino R, Spaziano G, D’Agostino B
Drug Design, Development and Therapy 2017, 11:265-272
Published Date: 23 January 2017
Role of biologics in severe eosinophilic asthma – focus on reslizumab
Pelaia G, Vatrella A, Busceti MT, Gallelli L, Preianò M, Lombardo N, Terracciano R, Maselli R
Therapeutics and Clinical Risk Management 2016, 12:1075-1082
Published Date: 1 July 2016
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Lombardo N, Maselli R
Therapeutics and Clinical Risk Management 2015, 11:1563-1572
Published Date: 8 October 2015
Dupilumab: a novel treatment for asthma
Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G
Journal of Asthma and Allergy 2014, 7:123-130
Published Date: 4 September 2014
Update on optimal use of omalizumab in management of asthma
Pelaia G, Gallelli L, Renda T, Romeo P, Busceti MT, Grembiale RD, Maselli R, Marsico SA, Vatrella A
Journal of Asthma and Allergy 2011, 4:49-59
Published Date: 13 June 2011